Credit Suisse Thinks Quest Diagnostics Inc’s Stock is Going to Recover

By Ryan Adsit

In a report released yesterday, A.J. Rice from Credit Suisse maintained a Buy rating on Quest Diagnostics Inc (DGXResearch Report), with a price target of $121. The company’s shares closed yesterday at $87.94, close to its 52-week low of $87.40.

According to, Rice is a 5-star analyst with an average return of 11.7% and a 67.1% success rate. Rice covers the Services sector, focusing on stocks such as AMN Healthcare Services Inc, Genesis Healthcare, and Acadia Healthcare.

Quest Diagnostics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $109.83, representing a 24.9% upside. In a report issued on November 20, Mizuho Securities also reiterated a Buy rating on the stock with a $108 price target.


See today’s analyst top recommended stocks >>

Quest Diagnostics Inc’s market cap is currently $13.18B and has a P/E ratio of 14.19. The company has a Price to Book ratio of 2.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Quest Diagnostics, Inc. engages in the provision fo diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers.